Is AZTR (AZTR) Halal?

AMEX Healthcare United States $4M
✗ NOT HALAL
Confidence: 90/100
AZTR (AZTR) is Not Halal under AAOIFI Standard 21. While the debt ratio of 28.7% is acceptable, the cash and interest-bearing securities ratio of 235.1% exceeds the 30% threshold. AZTR operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 28.7%
/ 30%
235.1%
/ 30%
5.3%
/ 30%
1634.04%
/ 5%
✗ NOT HALAL
DJIM 28.7%
/ 33%
235.1%
/ 33%
5.3%
/ 33%
1634.04%
/ 5%
✗ NOT HALAL
MSCI 7.5%
/ 33%
61.9%
/ 33%
1.4%
/ 33%
1634.04%
/ 5%
✗ NOT HALAL
S&P 28.7%
/ 33%
235.1%
/ 33%
5.3%
/ 33%
1634.04%
/ 5%
✗ NOT HALAL
FTSE 7.5%
/ 33%
61.9%
/ 33%
1.4%
/ 50%
1634.04%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-2.25
P/B Ratio
0.7
EV/EBITDA
-0.2
EV: $2M
Revenue
$0
Beta
-1.5
Low volatility
Current Ratio
2.8

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -230.7%
Return on Assets (ROA) -110.7%

Cash Flow & Balance Sheet

Operating Cash Flow-$11M
Free Cash Flow-$11M
Total Debt$422,077
Debt-to-Equity11.1
Current Ratio2.8
Total Assets$5M

Price & Trading

Last Close$0.24
50-Day MA$0.22
200-Day MA$0.68
Avg Volume12.2M
Beta-1.5
52-Week Range
$0.10
$2.67

About AZTR (AZTR)

CEO
Mr. Francisco D. Salva
Employees
13
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
AMEX
Market Cap
$4M
Currency
USD

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is AZTR (AZTR) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), AZTR is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is AZTR's debt ratio?

AZTR's debt ratio is 28.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.5%.

What are AZTR's key financial metrics?

AZTR has a market capitalization of $4M. Return on equity stands at -230.7%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.